Cellentia
Private Company
Funding information not available
Overview
Cellentia operates as a niche CRO and biobank, leveraging its expertise in bioassay development and organoid technology to serve pharmaceutical and biotech clients. The company's dual model combines high-value service revenue with the sale of proprietary patient-derived organoid lines, which are established from primary tumor tissue and circulating tumor cells. This positions Cellentia as a translational research partner, enabling more predictive drug screening and precision medicine development. Its leadership team possesses deep industry experience from major pharma, providing a strong foundation for technical credibility and client trust.
Technology Platform
Proprietary platform for deriving and culturing patient-derived 3D tumor organoids from primary tissue and circulating tumor cells (CTCs), coupled with custom bioassay development capabilities including MSD, ELISA, and cell-based assays.
Opportunities
Risk Factors
Competitive Landscape
Cellentia competes with large, full-service CROs (e.g., LabCorp, Charles River) that offer assay services, and with specialized organoid companies (e.g., Crown Bioscience, Hubrecht Organoid Technology). Its differentiation lies in its niche focus on custom assay development coupled with a proprietary bank of patient-derived organoid models, and its leadership's deep pharma R&D experience.